Evidence map›Paper›PMID 39562382›Full record

ArticleEJNMMI research2024

First-in-human study of

Reindert F Oostveen, Kang H Zheng, Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, Tim C de Wit, Edwin Poel, Joel Aerts, Francois Rouzet, Erik S G Stroes and 4 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03422055 (Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03422055 phase1unknown statusnot on this map

Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m

TypeinterventionalSponsorAssistance Publique - Hôpitaux de ParisRan2018 to 2018Enrolled10ConditionsHealthy VolunteerArms99mTc-Fucoidan SPECT
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Reindert F Oostveen *Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Kang H Zheng *Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Yannick KaiserDepartment of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Nick S NurmohamedDepartment of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Jeffrey KroonDepartment of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Tim C de WitDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Edwin PoelDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Joel AertsNuclear Medicine Department, Bichat Hospital, APHP, Paris, France.
Francois RouzetNuclear Medicine Department, Bichat Hospital, APHP, Paris, France.
Erik S G StroesDepartment of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Didier LetourneurUMR-S U1148 INSERM, Laboratory for Vascular Translational Science (LVTS), Université Paris Cité, Université Sorbonne Paris Nord, 75018, Paris, France.
Hein J VerberneDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Cédric Chauvierre *UMR-S U1148 INSERM, Laboratory for Vascular Translational Science (LVTS), Université Paris Cité, Université Sorbonne Paris Nord, 75018, Paris, France.
Mia R Ståhle *Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. mia.stahle@utu.fi.ORCID http://orcid.org/0000-0002-5904-1312

Funding

Inserm Transfert FP7-NMP-2012-LARGE-6-309820
6 · The paper itself

Abstract

backgroundActivation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of

results

conclusions

trial registrationClinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739. Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.

Indexed as

DosimetryFucoidanP-selectinSPECTThrombus

Identifiers

PMID39562382
PMCPMC11576749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.